Rational Design of Combinations for the Treatment of Advanced Cancer


Short Communication

According to recent statistics, more than eight million people annually succumb to the disease in the world [1]. It is clear that we must work much harder in order to eliminate this disease in the next several decades.

Systemic immunotherapy for the treatment of cancer has been investigated for many decades and has struggled to become a key player in that regard.

Discovery of oncogenic drivers such as EGFR in non-small cell lung cancer revolutionized therapeutic management in several clinical settings [18]. Despite a number of clinical trials investigating combination strategy over the decade, combination therapy does not generally provide better outcome over single agent alone.

Clinical researchers need to work with scientists closely for designing rational trials.

Document Type

Response or Comment

Publication Date


Publication Title

Journal of Cancer Clinical Trials

First Page